The FACT-targeted drug CBL0137 enhances the effects of rituximab to inhibit B-cell non-Hodgkin’s lymphoma tumor growth by promoting apoptosis and autophagy

[1]  Eutteum Jeong,et al.  The FACT complex facilitates expression of lysosomal and antioxidant genes through binding to TFEB and TFE3 , 2022, Autophagy.

[2]  OUP accepted manuscript , 2022, Nucleic Acids Research.

[3]  K. Bhakat,et al.  The FAcilitates Chromatin Transcription (FACT) complex: Its roles in DNA repair and implications for cancer therapy. , 2021, DNA repair.

[4]  K. Bhakat,et al.  Histone chaperone FACT complex inhibitor CBL0137 interferes with DNA damage repair and enhances sensitivity of medulloblastoma to chemotherapy and radiation. , 2021, Cancer letters.

[5]  J. Pettitt,et al.  Dual Targeting of Chromatin Stability By The Curaxin CBL0137 and Histone Deacetylase Inhibitor Panobinostat Shows Significant Preclinical Efficacy in Neuroblastoma , 2021, Clinical Cancer Research.

[6]  A. Rosenwald,et al.  Rituximab plus high-dose chemotherapy (MegaCHOEP) or conventional chemotherapy (CHOEP-14) in young, high-risk patients with aggressive B-cell lymphoma: 10-year follow-up of a randomised, open-label, phase 3 trial. , 2021, The Lancet. Haematology.

[7]  A. Marczak,et al.  Two Faces of Autophagy in the Struggle against Cancer , 2021, International journal of molecular sciences.

[8]  Ruikun Hu,et al.  Cyclin A2/cyclin-dependent kinase 1-dependent phosphorylation of Top2a is required for S phase entry during retinal development in zebrafish. , 2021, Journal of genetics and genomics = Yi chuan xue bao.

[9]  M. Taheri,et al.  The emerging role of non-coding RNAs in the regulation of PI3K/AKT pathway in the carcinogenesis process. , 2021, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[10]  Anurag K. Singh,et al.  Stimulation of an anti-tumor immune response with “chromatin-damaging” therapy , 2021, Cancer Immunology, Immunotherapy.

[11]  G. Chamberlain,et al.  Induction , 2015, A Warning for Fair Women.

[12]  Yujie Tang,et al.  Effective inhibition of MYC-amplified group 3 medulloblastoma by FACT-targeted curaxin drug CBL0137 , 2020, Cell Death & Disease.

[13]  G. Stark,et al.  CBL0137 increases the targeting efficacy of Rovalpituzumab tesirine against tumour-initiating cells in small cell lung cancer , 2020, British Journal of Cancer.

[14]  W. Stevens,et al.  Molecular Genetics of Relapsed Diffuse Large B-Cell Lymphoma: Insight into Mechanisms of Therapy Resistance , 2020, Cancers.

[15]  K. Huntoon,et al.  The small molecule drug CBL0137 increases the level of DNA damage and the efficacy of radiotherapy for glioblastoma. , 2020, Cancer letters.

[16]  M. Komatsu,et al.  Monitoring Autophagy Flux and Activity: Principles and Applications , 2020, BioEssays : news and reviews in molecular, cellular and developmental biology.

[17]  D. Scott,et al.  Toward a New Molecular Taxonomy of Diffuse Large B-cell Lymphoma. , 2020, Cancer discovery.

[18]  F. Speleman,et al.  PRL3 enhances T cell acute lymphoblastic leukemia growth through suppressing T cell signaling pathways and apoptosis , 2020, Leukemia.

[19]  Ali F. Alsulami,et al.  Whole exome sequencing reveals NOTCH1 mutations in anaplastic large cell lymphoma and points to Notch both as a key pathway and a potential therapeutic target , 2020, Haematologica.

[20]  John G Doench,et al.  MYC Controls the Epstein-Barr Virus Lytic Switch. , 2020, Molecular cell.

[21]  W. El-Deiry,et al.  Targeting apoptosis in cancer therapy , 2020, Nature Reviews Clinical Oncology.

[22]  H. Maecker,et al.  IMPAIRED IMMUNE HEALTH IN SURVIVORS OF DIFFUSE LARGE B‐CELL LYMPHOMA (DLBCL): A LARGE POPULATION‐BASED STUDY , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  Dongqing Wei,et al.  Identification of chlorprothixene as a potential drug that induces apoptosis and autophagic cell death in acute myeloid leukemia cells , 2020, The FEBS journal.

[24]  U. Kees,et al.  Potent antileukemic activity of curaxin CBL0137 against MLL‐rearranged leukemia , 2020, International journal of cancer.

[25]  Sina Salari,et al.  C-Myc inhibition sensitizes pre-B ALL cells to the anti-tumor effect of vincristine by altering apoptosis and autophagy: Proposing a probable mechanism of action for 10058-F4. , 2019, European journal of pharmacology.

[26]  M. Perales,et al.  Modern management of relapsed and refractory aggressive B-cell lymphoma: A perspective on the current treatment landscape and patient selection for CAR T-cell therapy. , 2019, Blood reviews.

[27]  A. Feldman,et al.  Coactivation of NF-κB and Notch signaling is sufficient to induce B cell transformation and enables B-myeloid conversion. , 2019, Blood.

[28]  I. Ng,et al.  Histone chaperone FACT complex mediates oxidative stress response to promote liver cancer progression , 2019, Gut.

[29]  Xiaodong Zhao,et al.  The histone chaperone complex FACT promotes proliferative switch of G0 cancer cells , 2019, International journal of cancer.

[30]  Wei-Lin Jin,et al.  Curaxin CBL0137 Exerts Anticancer Activity via Diverse Mechanisms , 2018, Front. Oncol..

[31]  B. Manavathi,et al.  Nimbolide, a neem limonoid inhibits cytoprotective autophagy to activate apoptosis via modulation of the PI3K/Akt/GSK-3β signalling pathway in oral cancer , 2018, Cell Death & Disease.

[32]  E. Baehrecke,et al.  Life, death and autophagy , 2018, Nature Cell Biology.

[33]  Jiajun Fan,et al.  Activating Autophagy Enhanced the Antitumor Effect of Antibody Drug Conjugates Rituximab-Monomethyl Auristatin E , 2018, Front. Immunol..

[34]  Stefano Monti,et al.  Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes , 2018, Nature Medicine.

[35]  G. Stark,et al.  The FACT inhibitor CBL0137 Synergizes with Cisplatin in Small-Cell Lung Cancer by Increasing NOTCH1 Expression and Targeting Tumor-Initiating Cells. , 2018, Cancer research.

[36]  Maozhi Hu,et al.  w09, a novel autophagy enhancer, induces autophagy-dependent cell apoptosis via activation of the EGFR-mediated RAS-RAF1-MAP2K-MAPK1/3 pathway , 2017, Autophagy.

[37]  S. Nakajima,et al.  SSRP1 Cooperates with PARP and XRCC1 to Facilitate Single-Strand DNA Break Repair by Chromatin Priming. , 2017, Cancer research.

[38]  A. Gudkov,et al.  Anticancer drug candidate CBL0137, which inhibits histone chaperone FACT, is efficacious in preclinical orthotopic models of temozolomide-responsive and -resistant glioblastoma , 2016, Neuro-oncology.

[39]  A. Gudkov,et al.  Preclinical Validation of a Single-Treatment Infusion Modality That Can Eradicate Extremity Melanomas. , 2016, Cancer research.

[40]  Wei Li,et al.  Blockage of SSRP1/Ets-1/Pim-3 signalling enhances chemosensitivity of nasopharyngeal carcinoma to docetaxel in vitro. , 2016, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[41]  Qiulian Wu,et al.  Pharmacological Targeting of the Histone Chaperone Complex FACT Preferentially Eliminates Glioblastoma Stem Cells and Prolongs Survival in Preclinical Models. , 2016, Cancer research.

[42]  Chunxia Xiao,et al.  Momordin Ic couples apoptosis with autophagy in human hepatoblastoma cancer cells by reactive oxygen species (ROS)-mediated PI3K/Akt and MAPK signaling pathways. , 2016, Free radical biology & medicine.

[43]  Chien-Ju Lin,et al.  Honokiol induces autophagy of neuroblastoma cells through activating the PI3K/Akt/mTOR and endoplasmic reticular stress/ERK1/2 signaling pathways and suppressing cell migration. , 2016, Cancer letters.

[44]  F. Speleman,et al.  Therapeutic targeting of the MYC signal by inhibition of histone chaperone FACT in neuroblastoma , 2015, Science Translational Medicine.

[45]  Feng Wang,et al.  Piperlongumine induces apoptosis and autophagy in human lung cancer cells through inhibition of PI3K/Akt/mTOR pathway , 2015, International journal of immunopathology and pharmacology.

[46]  P. Schumacker,et al.  Mitochondrial ROS in cancer: initiators, amplifiers or an Achilles' heel? , 2014, Nature Reviews Cancer.

[47]  B. Bonavida.  Postulated mechanisms of resistance of B-cell non-Hodgkin lymphoma to rituximab treatment regimens: strategies to overcome resistance. , 2014, Seminars in oncology.

[48]  Iannis Aifantis,et al.  Notch signaling: switching an oncogene to a tumor suppressor. , 2014, Blood.

[49]  Zhihua Yang,et al.  Protection of neurons from high glucose-induced injury by deletion of MAD2B , 2014, Journal of cellular and molecular medicine.

[50]  J. Puyal,et al.  A critical role of autophagy in antileukemia/lymphoma effects of APO866, an inhibitor of NAD biosynthesis , 2014, Autophagy.

[51]  W. Zong,et al.  Chinese a Nti鄄 Cancer a Ssociation , 2022 .

[52]  F. Minutolo,et al.  Curaxins: A New Family of Non‐genotoxic Multitargeted Anticancer Agents , 2011, ChemMedChem.

[53]  A. Komar,et al.  Curaxins: Anticancer Compounds That Simultaneously Suppress NF-κB and Activate p53 by Targeting FACT , 2011, Science Translational Medicine.

[54]  J. Cowell,et al.  Constitutive Notch pathway activation in murine ZMYM2-FGFR1-induced T-cell lymphomas associated with atypical myeloproliferative disease. , 2011, Blood.

[55]  Z. Elazar,et al.  Regulation of autophagy by ROS: physiology and pathology. , 2011, Trends in biochemical sciences.

[56]  B. Sobhian,et al.  Concordant and opposite roles of DNA-PK and the "facilitator of chromatin transcription" (FACT) in DNA repair, apoptosis and necrosis after cisplatin , 2011, Molecular Cancer.

[57]  W. Yung,et al.  Cellular and in vivo activity of a novel PI3K inhibitor, PX-866, against human glioblastoma. , 2010, Neuro-oncology.

[58]  Jia Liu,et al.  Cyclin E Is Stabilized in Response to Replication Fork Barriers Leading to Prolonged S Phase Arrest* , 2009, The Journal of Biological Chemistry.

[59]  E. White,et al.  The Double-Edged Sword of Autophagy Modulation in Cancer , 2009, Clinical Cancer Research.

[60]  P. Kaldis,et al.  Mammalian cell-cycle regulation: several Cdks, numerous cyclins and diverse compensatory mechanisms , 2009, Oncogene.

[61]  J. León,et al.  Inhibition of cell differentiation: A critical mechanism for MYC-mediated carcinogenesis? , 2009, Cell cycle.

[62]  Yufang Shi,et al.  Apoptosis signaling pathways and lymphocyte homeostasis , 2007, Cell Research.

[63]  A. Ng,et al.  Diffuse large B-cell lymphoma. , 2007, Seminars in radiation oncology.

[64]  G. Evan,et al.  Autophagy inhibition enhances therapy-induced apoptosis in a Myc-induced model of lymphoma. , 2007, The Journal of clinical investigation.

[65]  Jinho Kim,et al.  YC-1 induces S cell cycle arrest and apoptosis by activating checkpoint kinases. , 2006, Cancer research.

[66]  I. Landais,et al.  Coupling caspase cleavage and ubiquitin–proteasome-dependent degradation of SSRP1 during apoptosis , 2006, Cell Death and Differentiation.

[67]  D. Reinberg,et al.  Facts about FACT and transcript elongation through chromatin. , 2004, Current opinion in genetics & development.

[68]  F. Levi-Schaffer,et al.  Role of reactive oxygen species (ROS) in apoptosis induction , 2000, Apoptosis.

[69]  Mitchell R. Smith.  Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance , 2003, Oncogene.

[70]  Hilde van der Togt,et al.  Publisher's Note , 2003, J. Netw. Comput. Appl..

[71]  J. Massagué,et al.  Myc suppression of the p21Cip1 Cdk inhibitor influences the outcome of the p53 response to DNA damage , 2002, Nature.

[72]  J. Massagué,et al.  Myc suppression of the p21(Cip1) Cdk inhibitor influences the outcome of the p53 response to DNA damage. , 2002, Nature.

[73]  Cynthia A. Schandl,et al.  Major DNA Fragmentation Is a Late Event in Apoptosis , 1997, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[74]  T. Hunter,et al.  Cyclins and cancer II: Cyclin D and CDK inhibitors come of age , 1994, Cell.

[75]  J. Puyal,et al.  Title : A critical role of autophagy in antileukemia / lymphoma effects of APO 866 , an inhibitor of NAD biosynthesis , 2022 .